<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02041494</url>
  </required_header>
  <id_info>
    <org_study_id>UCSF-NIDDK-1R21DK093006-01A1</org_study_id>
    <secondary_id>1R21DK093006-01A1</secondary_id>
    <nct_id>NCT02041494</nct_id>
  </id_info>
  <brief_title>Complex Ventral Hernia Repair Using Biologic or Synthetic Mesh</brief_title>
  <acronym>CVHR</acronym>
  <official_title>Study Comparing the Efficacy, Safety, and Cost of a Permanent, Synthetic Prosthetic Versus a Biologic Prosthetic in the One-stage Repair of Ventral Hernias in Clean and Contaminated Wounds.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hobart Harris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hernias are often treated using a prosthetic mesh to add support to the healing wound.&#xD;
      Prosthetic meshes have been used for decades to repair ventral hernias, level 1 data&#xD;
      regarding which type of mesh to use is limited. The purpose of this study is to compare the&#xD;
      effects, good and/or bad, of two types of prosthetic meshes: one that is made from pig skin&#xD;
      (called a &quot;biologic prosthetic&quot;), and one that is made in a laboratory (called a &quot;synthetic&#xD;
      prosthetic&quot;). This study will include some patients who have an infection in/near the hernia,&#xD;
      and other patients who do not have an infection. We expect the synthetic mesh to be&#xD;
      associated with a higher rate of early post-operative surgical site infection and fluid&#xD;
      collections (seromas), while we expect the biologic mesh to be associated with a higher rate&#xD;
      of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-blind, randomized study comparing the clinical efficacy and&#xD;
      overall costs of two prosthetic meshes in the repair of complex ventral hernias. The two&#xD;
      prosthetic meshes to be studied are Ventralight (Bard, Murray Hill, NJ), a synthetic mesh&#xD;
      chiefly made of polypropylene and Strattice (LifeCell, Branchburg, NJ), a biologic mesh&#xD;
      derived from porcine dermis. The study population will consist of patients who are in need of&#xD;
      a repair of a complex ventral hernia. Patients will be enrolled in the study for 24 months&#xD;
      following their operation or until they experience a recurrence of their hernia, whichever&#xD;
      occurs first. The primary outcome variable is recurrence and the secondary outcome variables&#xD;
      are post-operative surgical site infections and overall costs.&#xD;
&#xD;
      There is no universally agreed upon definition of what constitutes a &quot;complex&quot; ventral&#xD;
      hernia. For our purposes, a &quot;complex&quot; ventral hernia is one that involves a compromised&#xD;
      surgical field, in which gastrointestinal, biliary, or genitourinary procedures are&#xD;
      performed, one in which the wound class is considered clean-contaminated, contaminated, or&#xD;
      dirty due to other causes, such as infected meshes and enterocutaneous fistulas, or surgical&#xD;
      procedures conducted in patients with large ventral hernia defects (&gt;10 cm in any single&#xD;
      dimension).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Rising costs have made continuing the study untenable&#xD;
  </why_stopped>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">October 5, 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Had a Recurrence of Hernia, at Anytime, up to Two Years Following Repair.</measure>
    <time_frame>up to 24 months after surgery</time_frame>
    <description>Number of patients who had a recurrence of hernia, at anytime, up to two years following repair as determined by physical examination, ultrasound or CT scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced Surgical Site Infections.</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Number of patients who experienced surgical site infections as determined by physical examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Generic Measure of Health-related Quality of Life and Hernia-specific Measure of Quality of Life With a Focus on Abdominal Wall Function</measure>
    <time_frame>24 months after surgery</time_frame>
    <description>Quality of life will be measured using the SF-36 and the HerQLes surveys.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Surgical Site Occurrences</measure>
    <time_frame>Up to two years from surgery</time_frame>
    <description>Number of surgical site occurrences by type.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Other Surgical Complications</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Number of other surgical complications including: urinary tract infections, pneumonia, and Deep Vein Thrombosis/pulmonary embolism.</description>
  </other_outcome>
  <other_outcome>
    <measure>Activity Level</measure>
    <time_frame>24 months after surgery</time_frame>
    <description>Activity level will be measured using the Activity Assessment Scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Cost</measure>
    <time_frame>24 months after surgery</time_frame>
    <description>Overall costs will be measured using a combination approach comparing actual costs, allowed vs. paid amounts, and Medicare payment rates using diagnosis related groups (DRG) and resource-based relative value scale (RBRVS) data.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Hernia, Ventral</condition>
  <arm_group>
    <arm_group_label>Synthetic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biologic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ventralight</intervention_name>
    <arm_group_label>Synthetic</arm_group_label>
    <other_name>Ventralight ST Mesh</other_name>
    <other_name>K101851</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Strattice</intervention_name>
    <arm_group_label>Biologic</arm_group_label>
    <other_name>LTM Surgical Mesh</other_name>
    <other_name>K070560</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical evidence of a midline, ventral hernia, regardless of degree of wound&#xD;
             contamination, with the exception of class IV wounds due to the presence/discovery of&#xD;
             fecal peritonitis. Specifically, the repair will or will not involve a compromised&#xD;
             surgical field in which gastrointestinal, biliary and/or genitourinary procedures will&#xD;
             be performed. The surgical wound class may be classified as clean, or it may be&#xD;
             classified as clean-contaminated, contaminated, or dirty-infected, due to the repair&#xD;
             of an enterocutaneous fistula, takedown of an intestinal stoma and/or removal of&#xD;
             infected mesh&#xD;
&#xD;
          -  Age &gt;21&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No allergic, religious or ethical objections to either polypropylene or porcine&#xD;
             prosthetics&#xD;
&#xD;
          -  Signed, witnessed informed consent to take part in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lactating women&#xD;
&#xD;
          -  Patients who are unable to commit to the follow evaluations over 24 months&#xD;
&#xD;
          -  Severe malnutrition (serum albumin &lt;2.0 in the setting of a normal CRP)&#xD;
&#xD;
          -  Use of an investigational agent within 1 month prior to study enrollment and/or&#xD;
             planned during this study&#xD;
&#xD;
          -  Presence of pre-existing parenchymal liver disease characterized by the presence of&#xD;
             Child's Class C liver dysfunction (including all of the following: bilirubin ≥ 3.0&#xD;
             mg/dL; albumin ≤ 3.0 mg/dL; refractory ascites; encephalopathy or coma; and poor&#xD;
             nutritional status)&#xD;
&#xD;
          -  Immunocompromised patients, as evidenced by: administration of high doses of&#xD;
             corticosteroids (i.e. doses ≥ 1.5 mg/kg/day of prednisone or equivalent) within 72&#xD;
             hours before study enrollment; status post solid organ transplant or bone marrow&#xD;
             transplant and experiencing acute organ rejection or bone marrow failure or rejection;&#xD;
             evidence of neutropenia (absolute neutrophil count ≤ 500 cells/mm3 (≤ 500 x 106&#xD;
             cells/L); chemotherapy or radiation therapy within 90 days before study enrollment;&#xD;
             known AIDS; any disease sufficiently advanced to suppress resistance to infection&#xD;
             (including, but not limited to leukemia, lymphoma or hypogammaglobulinemia);&#xD;
             administration of immunoglobulin of G-CSF within 90 days before study enrollment&#xD;
&#xD;
          -  Ascites refractory to medical management&#xD;
&#xD;
          -  Presence of an underlying disease/injury with life expectancy less than two years&#xD;
             and/or severe underlying disease that would preclude study entry (e.g. known&#xD;
             malignancy)&#xD;
&#xD;
          -  Wound Classification IV due to the presence/discovery of fecal peritonitis. Other&#xD;
             cases of wound class IV including presence of purulent inflammation, soft tissue/mesh&#xD;
             infection, or visceral perforation resulting in a contained fistula (e.g.&#xD;
             enterocutaneous fistula) are still considered eligible for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hobart W. Harris, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Harris HW, Primus F, Young C, Carter JT, Lin M, Mukhtar RA, Yeh B, Allen IE, Freise C, Kim E, Sbitany H, Young DM, Hansen S. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial. Ann Surg. 2021 Apr 1;273(4):648-655. doi: 10.1097/SLA.0000000000004336.</citation>
    <PMID>33443907</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <results_first_submitted>February 19, 2021</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Hobart Harris</investigator_full_name>
    <investigator_title>Professor, Chief of General Surgery</investigator_title>
  </responsible_party>
  <keyword>Hernia</keyword>
  <keyword>Ventral</keyword>
  <keyword>Incisional</keyword>
  <keyword>Abdominal</keyword>
  <keyword>Herniorrhaphy</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Infection</keyword>
  <keyword>Mesh</keyword>
  <keyword>Biologic</keyword>
  <keyword>Synthetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02041494/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 23, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02041494/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults (≥21 years of age) with a ventral hernia scheduled for an elective repair were eligible for inclusion. Recruitment and all surgical procedures were carried out from March 2014 through October 2018 at UCSF Medical Center). All participants were recruited via referral to the medical center's surgery clinics. Patients were only enrolled once.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Biologic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
        </group>
        <group group_id="P2">
          <title>Synthetic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synthetic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
        </group>
        <group group_id="B2">
          <title>Biologic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="11.1"/>
                    <measurement group_id="B2" value="55.0" spread="11.5"/>
                    <measurement group_id="B3" value="55.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Had a Recurrence of Hernia, at Anytime, up to Two Years Following Repair.</title>
        <description>Number of patients who had a recurrence of hernia, at anytime, up to two years following repair as determined by physical examination, ultrasound or CT scan.</description>
        <time_frame>up to 24 months after surgery</time_frame>
        <population>This measure includes patients that recurred before 2 years and were not followed for 2 years, and some patients that recurred were followed for 2 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
          </group>
          <group group_id="O2">
            <title>Synthetic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had a Recurrence of Hernia, at Anytime, up to Two Years Following Repair.</title>
          <description>Number of patients who had a recurrence of hernia, at anytime, up to two years following repair as determined by physical examination, ultrasound or CT scan.</description>
          <population>This measure includes patients that recurred before 2 years and were not followed for 2 years, and some patients that recurred were followed for 2 years.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced Surgical Site Infections.</title>
        <description>Number of patients who experienced surgical site infections as determined by physical examination.</description>
        <time_frame>30 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Biologic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
          </group>
          <group group_id="O2">
            <title>Synthetic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Surgical Site Infections.</title>
          <description>Number of patients who experienced surgical site infections as determined by physical examination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Generic Measure of Health-related Quality of Life and Hernia-specific Measure of Quality of Life With a Focus on Abdominal Wall Function</title>
        <description>Quality of life will be measured using the SF-36 and the HerQLes surveys.</description>
        <time_frame>24 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Surgical Site Occurrences</title>
        <description>Number of surgical site occurrences by type.</description>
        <time_frame>Up to two years from surgery</time_frame>
        <population>Only patients with a surgical site occurrence were included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
          </group>
          <group group_id="O2">
            <title>Synthetic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.&#xD;
Ventralight</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Surgical Site Occurrences</title>
          <description>Number of surgical site occurrences by type.</description>
          <population>Only patients with a surgical site occurrence were included in this outcome measure.</population>
          <units>surgical site occurence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound necrosis and other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Other Surgical Complications</title>
        <description>Number of other surgical complications including: urinary tract infections, pneumonia, and Deep Vein Thrombosis/pulmonary embolism.</description>
        <time_frame>30 days after surgery</time_frame>
        <population>Only patients with other surgical complications were included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Biologic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
          </group>
          <group group_id="O2">
            <title>Synthetic</title>
            <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Other Surgical Complications</title>
          <description>Number of other surgical complications including: urinary tract infections, pneumonia, and Deep Vein Thrombosis/pulmonary embolism.</description>
          <population>Only patients with other surgical complications were included in this outcome measure.</population>
          <units>occurence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urinary tract infection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep Vein Thrombosis/pulmonary embolism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Activity Level</title>
        <description>Activity level will be measured using the Activity Assessment Scale.</description>
        <time_frame>24 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Cost</title>
        <description>Overall costs will be measured using a combination approach comparing actual costs, allowed vs. paid amounts, and Medicare payment rates using diagnosis related groups (DRG) and resource-based relative value scale (RBRVS) data.</description>
        <time_frame>24 months after surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected throughout the duration of the study, an average of 26 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Biologic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.&#xD;
Strattice</description>
        </group>
        <group group_id="E2">
          <title>Synthetic</title>
          <description>Patients in this arm will have their ventral hernia repaired utilizing a synthetic prosthetic mesh made of polypropylene.&#xD;
SoftMesh/Ventralight ST</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>deep space infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DVT/pumonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>superficial SSI</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="82"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="82"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hobart W. Harris, Chief of General Surgery</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 514-3891</phone>
      <email>hobart.harris@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

